March 17 (Reuters) - Pfizer said on Tuesday its experimental combination reduced the risk of disease progression or death by 40% in patients with breast cancer. Here are some details: * Pfizer's ...

One of oncology's biggest challenges is that the same treatment can work well for some patients but fail completely in others ...

A triple drug approach that blocks the KRAS pathway at three points eliminated pancreatic tumors and prevented resistance in ...

Pfizer is betting on a new breast cancer drug combo that, in a key mid-stage trial, cut the risk of the disease worsening or ...

The finding suggests other chemo drugs, too, may be making cancer cells cause a surprising immune-system reaction.

Therapeutic progress in lung squamous cell carcinoma has lagged, with recent antiangiogenic–checkpoint inhibitor combinations failing primary endpoints despite improved safety, underscoring unmet need ...

Baylor University researchers have developed a novel approach to fight colorectal cancer, using modified bacteria as a courier to deliver potent cancer-killing proteins into tumor cells. Michael S.

Discover SonoPIN, a groundbreaking technique that uses ultrasound and microbubbles for targeted cancer treatment.

The FDA's cancer advisors will discuss AstraZeneca’s application for the oral SERD camizestrant in breast cancer and the AKT ...

In a study of adults with advanced prostate cancer taking androgen-receptor pathway inhibitors and different types of ...

This clinical-stage biotech develops oncology therapeutics and partners with leading institutions in cancer and immunology research.